PTHS

Pelthos Therapeutics Inc.

8.90

USD

-0.47

-5.02%

Nov 10, 15:59 UTC -5

Closed

After-Market

8.90

0.00

0.00%

Pelthos Therapeutics Inc. (PTHS) Earnings

PTHS Earnings Reports

Positive Surprise Ratio

PTHS beat 3 of 8 last estimates.

38%

Next Report

In 2 Days

Date of Next Report

Nov 12, 2026

Estimate for Q3 26 (Revenue/ EPS)

$17.96M

-$2.20

Implied change from Q2 26 (Revenue/ EPS)

+15.09%

-57.12%

Implied change from Q3 25 (Revenue/ EPS)

+142.47%

-58.49%

Pelthos Therapeutics Inc. earnings per share and revenue

On Aug 13, 2026, PTHS reported earnings of -5.13 USD per share (EPS) for Q2 26, missing the estimate of -3.10 USD, resulting in a -65.05% surprise. Revenue reached 15.60 million, compared to an expected 15.58 million, with a 0.16% difference. The market reacted with a +0.14% price change (close before vs. close after earnings).

Looking ahead to Q3 26, -- analysts forecast an EPS of -2.20 USD, with revenue projected to reach 17.96 million USD, implying an decrease of -57.12% EPS, and increase of 15.09% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

CalciMedica, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$1.30

Actual

-$0.72

Surprise

+44.64%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.03

Actual

$0.05

Surprise

+265.02%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

FAQ

What were Pelthos Therapeutics Inc.'s earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Pelthos Therapeutics Inc. reported EPS of -$5.13, missing estimates by -65.05%, and revenue of $15.60M, 0.16% above expectations.

How did the market react to Pelthos Therapeutics Inc.'s Q2 2026 earnings?

The stock price moved up 0.14%, changed from $28.91 before the earnings release to $28.95 the day after.

When is Pelthos Therapeutics Inc. expected to report next?

The next earning report is scheduled for Nov 12, 2026.

What are the forecasts for Pelthos Therapeutics Inc.'s next earnings report?

Based on -- analysts, Pelthos Therapeutics Inc. is expected to report EPS of -$2.20 and revenue of $17.96M for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.